FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 723 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib December 1, 2022 Taking Control – Risks vs. Benefits July 14, 2020 A new year of expanding research horizons January 21, 2022 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Load more HOT NEWS Research shows one size doesn’t fit all for cervical screening in... To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells
